Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 4, 2007, Pages 477-483

  Keiser, Philip ^a,b   Nassar, Naiel ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abacavir sulfate; HIV; Lamivudine; Trizivir ; Zidovudine

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; CYTOTOXIC AGENT; DIDANOSINE; EFAVIRENZ; ERYTHROPOIETIN; GANCICLOVIR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; METHADONE; NELFINAVIR; NUCLEOSIDE ANALOG; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERANCE; FATIGUE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY; INFLUENZA; LACTIC ACIDOSIS; LIPID DIET; MONOTHERAPY; MYOPATHY; NAUSEA; NEUROPATHY; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TEST; THROMBOCYTOPENIA; VIRUS LOAD; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LAMIVUDINE; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 33947281151     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.4.477     Document Type: Review

References (39)

1. DUBE MP: Lipodystrophy and insulin resistance in patients with HIV. J. Acquir. Immune Defic. Syndr. (2001) 27(5):506-507.
2. MARTINEZ E, GARCIA-VIEJO MA, BLANCH L, GATELL JM: Lipodystrophy syndrome in patients with HIV infection: quality of life issues. Drug Saf. (2001) 24(3):157-166.
3. BOUFASSA F, DULIOUST A, LASCAUX AS et al.: Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin. Trials (2001) 2(4):339-345.
4. GLAXOSMITHKLINE: Trizivir® (abacavir sulfate, lamivudine, and zidovudine) prescribing information. GlaxoSmithKline, Research Triangle Park (NC) USA (2006).
5. CHITTICK GE, GILLOTIN C, MCDOWELL JA et al.: Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy (1999) 19(8):932-942.
6. MCDOWELL JA, CHITTICK GE, STEVENS CP, EDWARDS KD, STEIN DS: Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. (2000) 44(6):1686-1690.
7. MCDOWELL JA, LOU Y, SYMONDS WS, STEIN DS: Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. (2000) 44(8):2061-2067.
8. VAN PRAAG RM, VAN HEESWIJK RP, JURRIAANS S, LANGE JM, HOETELMANS RM, PRINS JM: Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus Type 1. Clin. Infect. Dis. (2001) 33(8):e91-e92.
9. YUEN GJ, LOU Y, THOMPSON NF et al.: Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption. J. Clin. Pharmacol. (2001) 41(3):277-288.
10. CREMIEUX AC, KATLAMA C, GILLOTIN C et al.: A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. Pharmacotherapy (2001) 21(4):424-430.
11. IZZEDINE H, LAUNAY-VACHER V, AYMARD G, LEGRAND M, DERAY G: Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. Nephron (2001) 89(1):62-67.
12. BART PA, RIZZARDI PG, GALLANT S et al.: Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther. Drug Monit. (2001) 23(5):553-555.
13. FISCHL MA: Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection. AIDS (1999) 13(Suppl. 1):S49-S59.
14. STASZEWSKI S, KATLAMA C, HARRER T et al.: A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS (1998) 12(16):F197-F202.
15. HENRY K, WALLACE RJ, BELLMAN PC et al.: Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus Type 1: results of the TARGET Study. J. Infect. Dis. (2001) 183(4):571-578.
16. CLUMECK N, GOEBEL F, ROZENBAUM W et al.: Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. Aids (2001) 15(12):1517-1526.
17. STASZEWSKI S, KEISER P, MONTANER J et al.: Abacavir-lamivudine-zidovudine versus indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA (2001) 285(9):1155-1163.
18. VIBHAGOOL A, CAHN P, SCHECHTER M et al.: Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naive adults: results of a 48-week open-label, equivalence trial (CNA3014). Curr. Med. Res. Opin. (2004) 20(7):1103-1114.
19. MATHERON S, DESCAMPS D, BOUE F et al.: Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir. Ther. (2003) 8(2):163-171.
20. GULICK RM, RIBAUDO HJ, SHIKUMA CM et al.: Three- versus four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA (2006) 296(7):769-781.
21. GULICK RM, RIBAUDO HJ, SHIKUMA CM et al.: Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. (2004) 350(18):1850-1861.
22. KATLAMA C, FENSKE S, GAZZARD B et al.: TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med. (2003) 4(2):79-86.
23. MARKOWITZ M, HILL-ZABALA C, LANG J et al.: Induction with abacavir/ lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. (2005) 39(3):257-264.
24. SHAPIRO M, WARD KM, STERN JJ: A near-fatal hypersensitivity reaction to abacavir: case report and literature review. AIDS Read (2001) 11(4):222-226.
25. FRISSEN PH, DE VRIES J, WEIGEL HM, BRINKMAN K: Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity AIDS (2001) 15(2):289.
26. ESCAUT L, LIOTIER JY, ALBENGRES E, CHEMINOT N, VITTECOQ D: Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS (1999) 13(11):1419-1420.
27. PEYRIEERE H, NICOLAS J, SIFFERT M, DEMOLY P. HILLAIRE-BUYS D, REYNES J: Hypersensitivity related to abacavir in two members of a family. Ann. Pharmacother. (2001) 35(10):1291-1292.
28. HETHERINGTON S, HUGHES AR, MOSTELLER M et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet (2002) 359(9312):1121-1122.
29. MALLAL S, NOLAN D, WITT C et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet (2002) 359(9308):727-732.
30. MARTIN AM, NOLAN D, GAUDIERI S: Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. USA (2004) 101(12):4180-4185.
31. RAUCH A, NOLAN D, MARTIN A, MCKINNON E, ALMEIDA C, MALLAL S: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin. Infect. Dis. (2006) 43(1):99-102.
32. PHILLIPS EJ, SULLIVAN JR, KNOWLES SR, SHEAR NH: Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS (2002) 16(16):2223-2225.
33. JOHNSON AA, RAY AS, HANES J et al.: Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem. (2001) 276(44):40847-40857.
34. KAKUDA TN: Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity Clin. Ther. (2000) 22(6):685-708.
35. TIKHOMIROV V, NAMEK K, HINDES R: Agranulocytosis induced by abacavir. Aids (1999) 13(11):1420-1421.
36. LANIER ER, AIT-KHALED M, SCOTT J et al.: Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir. Ther. (2004) 9(1):37-45.
37. LATHAM V, STEBBING J, MANDALIA S et al.: Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol. J. Antimicrob. Chemother. (2005) 56(1):186-189.
38. SOSA N, HILL-ZABALA C, DEJESUS E et al.: Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). J. Acquir. Immune Defic. Syndr. (2005) 40(4):422-427.
39. FALLOON J, AIT-KHALED M, THOMAS DA et al.: HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS (2002) 16(3):387-396.